시장보고서
상품코드
1193141

세계의 분아균증 시장 : 제제별, 약제 유형별, 유통 채널별-기회 분석, 산업 예측(2021-2031년)

Blastomycosis Market By Formulation, By Drug Type, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031

발행일: | 리서치사: Allied Market Research | 페이지 정보: 영문 240 Pages | 배송안내 : 2-3일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

분아균증(Blastomycosis)은 목재나 토양에 서식하는 블라스트미세스 델마티디스라는 곰팡이로 인한 곰팡이 감염의 일종입니다.

블라스트 마이세스의 포자를 흡입하면 공기를 통해 체내로 들어가기 때문에 주로 폐를 침범하고 폐렴을 일으 킵니다. 곰팡이는 혈액을 통해 신체의 다른 부위로 퍼집니다. 분아균증의 증상은 다른 폐 감염증의 증상과 닮은 경우가 많으며, 기침, 침한 땀, 근육통과 관절통, 체중감소, 흉통, 피로감 등이 있습니다.

분아균증 감염이 피부에 퍼진 경우, 경도에서 중등도의 경우에는 아졸, 알릴아민, 에키노캔딘, 폴리엔 등 치료제를 투여할 수 있습니다.

분아균증 시장의 성장을 견인하는 주요 요인으로는 분아균증 치료를 위한 신약 개발 증가, 폐렴, 결핵, 비감염성 폐질환 등 만성질환의 유병률 상승에 의한 분아균증 환자 증가, 분아균증의 치료에 있어서 아졸계의 높은 보급률 등을 들 수 있습니다. 또한, 감염증의 발생률과 유병률 증가, 면역부전자(감염증에 걸리기 쉬운 사람) 증가가 시장의 성장을 촉진합니다.

예를 들어, 미국 질병 예방 센터에 따르면, 2021년 미국에서 보고된 결핵(TB) 환자는 7,860명(10만명당 2.4명의 비율)입니다. 미국에서는 최대 1,300만 명이 잠재성 결핵 감염을 갖고 생활했습니다. 이 때문에 블라스토마이시스 환자 수가 증가하고 블라스토마이시스 치료에 대한 수요가 높아지고 있습니다. 따라서 이러한 요인은 분아균증 치료제의 성장을 촉진합니다.

예를 들어 세계보건기구(WHO)에 따르면 2021년 세계에서 3480만 명이 HIV와 공존하고 65만 명이 HIV 관련 질병으로 사망하고 있다고 합니다. 이에 따르면 2021년 HIV를 취득하는 사람은 150만명. 따라서, 이러한 HIV 환자들은 HIV에 대한 면역력이 약하기 때문에 분아균증에 걸리기 쉽습니다.

그러나 불리한 상환뿐만 아니라 마약이나 분아균증의 약물의 막대한 비용 등으로 시장의 성장을 방해 할 것으로 예상됩니다. 한편, 신흥 국가의 암메트 메디컬 디맨드와 신흥 국가의 유리한 비즈니스 기회는 향후 전세계의 분아균증 치료제 제조사에게 절대적인 비즈니스 기회를 가져올 것으로 기대되고 있습니다.

또한, 건강관리사업은 면역부전 환자 증가, 후천성 면역부전 증후군(AIDS)의 유행에 의해 분아균증에 걸리기 쉬워 분아균증 시장의 성장을 뒷받침하기 때문에 성장을 보일 것으로 예측됩니다. 또한 분아균증에 대한 안전하고 효과적인 치료제의 발견·개발 증가와 분아균증의 치료에 있어서 아졸계 약제의 사용에 관한 의식 증가가 분아균증 시장의 성장을 뒷받침합니다. 이 때문에 예측기간 동안 주요 기업이 시장에 투자할 수 있는 유익한 기회를 제공할 것으로 예상됩니다.

또한 R&D 투자 증가, 아졸을 이용한 임상연구 증가, 선진국의 자본소득 증가, 주요 기업이 채택하는 인수, 제휴, 제품 출시 등 주요 전략의 급증은 시장의 수요를 강화합니다.

예를 들어, 2021년 6월, Celon Laboratories Pvt. Ltd.는 곰팡이 감염의 치료에 사용되는 암포테리신 B 에멀젼 'AMFIGHT'의 출시를 발표했습니다. 이 에멀젼 기반 제제는 리포좀 암포테리신 B를 대체하는 흑색 곰팡이 대책에 가장 적합한 제형입니다. 셀론은 2013년부터 리포솜 암포테리신 B를 제조하고 있지만 독일에서 조달한 중요한 성분인 리포이드를 입수할 수 없기 때문에 시장 수요에 부응하지 못했습니다. 이 조달 장애로 인한 병목 현상을 피하고 이 약의 생산량을 늘리기 위해 셀론은 대체 에멀젼 기반 제형을 개발했습니다. AMFIGHT의 발매는 기업의 항진균제 제품군의 강화로 이어집니다. 이런 종류의 제품 출시는 분아균증 시장의 성장을 뒷받침합니다.

목차

제1장 소개

제2장 주요 요약

제3장 시장 개요

  • 시장 정의와 범위
  • 주요 조사 결과
    • 주요 투자 포켓
  • Porter’s Five Forces
  • 주요 기업의 포지셔닝
  • 시장 역학
    • 촉진 요인
    • 억제 요인
    • 기회
  • COVID-19 영향 분석

제4장 분아균증 시장 : 제제별

  • 개요
    • 시장 규모 및 예측
  • 정제
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모 및 예측 : 지역별
    • 시장 점유율 분석 : 국가별
  • 연고
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모 및 예측 : 지역별
    • 시장 점유율 분석 : 국가별
  • 분말
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모 및 예측 : 지역별
    • 시장 점유율 분석 : 국가별
  • 액체
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모 및 예측 : 지역별
    • 시장 점유율 분석 : 국가별

제5장 분아균증 시장 : 약제 유형별

  • 개요
    • 시장 규모 및 예측
  • 아졸계
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모 및 예측 : 지역별
    • 시장 점유율 분석 : 국가별
  • 폴리엔류
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모 및 예측 : 지역별
    • 시장 점유율 분석 : 국가별
  • 기타
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모 및 예측 : 지역별
    • 시장 점유율 분석 : 국가별

제6장 분아균증 시장 : 유통 채널별

  • 개요
    • 시장 규모 및 예측
  • 병원·조제 약국
    • 주요 시장 동향, 성장 요인과 기회
    • 시장 규모 및 예측 : 지역별
    • 시장 점유율 분석 : 국가별
  • 온라인 약국
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모 및 예측 : 지역별
    • 시장 점유율 분석 : 국가별
  • 소매 약국
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모 및 예측 : 지역별
    • 시장 점유율 분석 : 국가별

제7장 분아균증 시장 : 지역별

  • 개요
    • 시장 규모 및 예측
  • 북미
    • 주요 동향 및 기회
    • 북미의 시장 규모 및 예측 : 제형별
    • 북미의 시장 규모 및 예측 : 약제 유형별
    • 북미의 시장 규모 및 예측 : 유통 채널별
    • 북미의 시장 규모 및 예측 : 국가별
      • 미국
      • 캐나다
      • 멕시코
  • 유럽
    • 주요 동향 및 기회
    • 유럽의 시장 규모 및 예측 : 제제별
    • 유럽의 시장 규모 및 예측 : 약제 유형별
    • 유럽의 시장 규모 및 예측 : 유통 채널별
    • 유럽의 시장 규모 및 예측 : 국가별
      • 독일
      • 프랑스
      • 영국
      • 이탈리아
      • 스페인
      • 기타 유럽 지역
  • 아시아 태평양 지역
    • 주요 동향 및 기회
    • 아시아 태평양 지역의 시장 규모 및 예측 : 제제별
    • 아시아 태평양 지역의 시장 규모 및 예측 : 약제 유형별
    • 아시아 태평양 지역의 시장 규모 및 예측 : 유통 채널별
    • 아시아 태평양 지역의 시장 규모 및 예측 : 국가별
      • 중국
      • 인도
      • 호주
      • 한국
      • 기타 아시아 태평양 지역
  • LAMEA
    • 주요 동향 및 기회
    • LAMEA의 시장 규모 및 예측 : 제제별
    • LAMEA의 시장 규모 및 예측 : 약제 유형별
    • LAMEA의 시장 규모 및 예측 : 유통 채널별
    • LAMEA의 시장 규모 및 예측 : 국가별
      • 브라질
      • 남아프리카 공화국
      • 사우디 아라비아
      • 기타 LAMEA 지역

제8장 기업 정세

  • 소개
  • 주요 성공 전략
  • 주요 10개사의 제품 매핑
  • 경쟁 대시보드
  • 경합의 히트 맵
  • 주요 발전

제9장 기업 개요

  • Pfizer Inc.
  • Sanofi
  • Merck and Company
  • GSK
  • johnson and johnson md&d
  • Abbott Laboratories
  • CELON LABORATORIES LIMITED
  • Sun Pharmaceuticals Ltd
  • Astellas Pharma Inc.
  • Cipla Ltd
LSH 23.03.13

Blastomycosis is a type of fungal infection caused by the fungus Blastomyces dermatitidis, which grows in wood and soil. Spores of Blastomyces enter the body through air, when inhaled, thus it mainly affects the lung and causes pneumonia. Fungi are spread through the bloodstream to other parts of the body. The symptoms of blastomycosis are often similar to the symptoms of other lung infections and can include cough, night sweats, muscle aches or joint pain, weight loss, chest pain, and fatigue.

When blastomycosis infection is spread in the skin, treatments such as azole, allylamines, echinocandins, and polyenes can be given in mild to moderate cases of blastomycosis infection.

Major factors driving the growth of the blastomycosis market include a rise in the development of new medicine for the treatment of blastomycosis infection, an increase in the prevalence rate of chronic diseases such as pneumonia, tuberculosis, a non-infectious pulmonary disease that have led to increases in a number of blastomycosis patients, and high adoption of azoles for the treatment of blastomycosis. Further, growth in the incidence and prevalence rate of infectious diseases and the rise in the population of immunocompromised (prone to infectious diseases) individuals enhance the growth of this market.

For instance, according to the Centers for Disease Control and Prevention, 7,860 tuberculosis (TB) cases were reported in the U.S. in 2021 (a rate of 2.4 per 100,000 persons). In the U.S., up to 13 million people live with latent TB infection. This has led to an increase in the number of blastomycosis patients, which increases the demand for blastomycosis treatment. Hence, such factors drive the growth of blastomycosis treatment.

For instance, according to World Health Organization (WHO), 34.8 million people were living with HIV worldwide in 2021 and 650,000 people died of HIV-related illnesses worldwide in 2021. According to this 1.5 million people acquiring HIV in 2021. Hence, these HIV patients are more vulnerable to blastomycosis, owing to weak immunity to HIV.

However, unfavorable reimbursements as well as complications such as high costs of medicine and drugs for blastomycosis are expected to hamper the market growth. On the contrary, unmet medical demands in developing countries and lucrative opportunities in emerging economies are expected to create immense opportunities for blastomycosis medicine manufacturers worldwide in the future.

Furthermore, the healthcare business is projected to witness growth owing to a rise in immunocompromised patients, a rise in the prevalence of acquired immunodeficiency syndrome (AIDS), that are more vulnerable to blastomycosis, and a boost in the growth of the blastomycosis market. In addition, an increase in the discovery & development of safe and effective medicine for blastomycosis and a rise in awareness regarding the use of azoles for the treatment of blastomycosis drive the growth of the blastomycosis market. This is anticipated to offer remunerative opportunities for key players to invest in the market during the forecast period.

Moreover, a rise in R&D investments, an increase in azoles-assisted clinical research studies, a significant rise in the capital income in developed countries, and a surge in key strategies such as acquisition, collaboration, and product launch, adopted by key players strengthen the demand for blastomycosis in the market.

For instance, in June 2021, Celon Laboratories Pvt. Ltd. announced the launch of AMFIGHT, an amphotericin B emulsion, used in the treatment of fungal infection. The emulsion-based formulation is an ideal alternative to Liposomal Amphotericin B to combat the Black Fungus. Though Celon has been manufacturing Liposomal Amphotericin B since 2013, market demands were not met due to the unavailability of a critical ingredient sourced from Germany - lipoids. To bypass the bottleneck caused by this sourcing obstacle and increase the production of this medication, Celon developed an alternative, an emulsion-based formulation. The launch of AMFIGHT will help the company to strengthen its anti-fungal product portfolio. This type of product launch boosts the growth of the blastomycosis market.

The blastomycosis market is segmented on the basis of formulation, drug type, distribution channel, and region. On the basis of formulation, the market is classified into tablets, ointment, powder, and liquid. On the basis of drug type, the market is classified into azoles, polyenes, and others. Depending on the distribution channel, it is fragmented into hospital & clinical pharmacy, online pharmacy, and retail pharmacy. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and the rest of Europe), Asia-Pacific (China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major players profiled in the report are Abbott Laboratories, Astellas Pharma Inc., Celon Laboratories Pvt. Ltd., Cipla Ltd, GlaxoSmithKline plc, Johnson and Johnson, Merck KGaA, Pfizer Inc., Sanofi S.A., and Sun Pharmaceutical Industries Ltd.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the blastomycosis market analysis from 2021 to 2031 to identify the prevailing blastomycosis market opportunities.

Market research is offered along with information related to key drivers, restraints, and opportunities.

Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make profit-oriented business decisions and strengthen their supplier-buyer network.

An in-depth analysis of the blastomycosis market segmentation assists to determine the prevailing market opportunities.

Major countries in each region are mapped according to their revenue contribution to the global market.

Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

The report includes an analysis of the regional as well as global blastomycosis market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug Type

  • Azoles
  • Polyenes
  • Others

By Distribution Channel

  • Hospital and Clinical Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

By Formulation

  • Tablets
  • Ointment
  • Powder
  • Liquid

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA
  • Key Market Players
    • Pfizer Inc.
    • Sanofi
    • Merck and Company
    • GSK
    • johnson and johnson md&d
    • Abbott Laboratories
    • CELON LABORATORIES LIMITED
    • Sun Pharmaceuticals Ltd
    • Astellas Pharma Inc.
    • Cipla Ltd

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: BLASTOMYCOSIS MARKET, BY FORMULATION

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Tablets
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market share analysis by country
  • 4.3 Ointment
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market share analysis by country
  • 4.4 Powder
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market share analysis by country
  • 4.5 Liquid
    • 4.5.1 Key market trends, growth factors and opportunities
    • 4.5.2 Market size and forecast, by region
    • 4.5.3 Market share analysis by country

CHAPTER 5: BLASTOMYCOSIS MARKET, BY DRUG TYPE

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Azoles
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market share analysis by country
  • 5.3 Polyenes
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market share analysis by country
  • 5.4 Others
    • 5.4.1 Key market trends, growth factors and opportunities
    • 5.4.2 Market size and forecast, by region
    • 5.4.3 Market share analysis by country

CHAPTER 6: BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Hospital and Clinical Pharmacy
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market share analysis by country
  • 6.3 Online Pharmacy
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market share analysis by country
  • 6.4 Retail Pharmacy
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market share analysis by country

CHAPTER 7: BLASTOMYCOSIS MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Formulation
    • 7.2.3 North America Market size and forecast, by Drug Type
    • 7.2.4 North America Market size and forecast, by Distribution Channel
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Key market trends, growth factors and opportunities
      • 7.2.5.1.2 Market size and forecast, by Formulation
      • 7.2.5.1.3 Market size and forecast, by Drug Type
      • 7.2.5.1.4 Market size and forecast, by Distribution Channel
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Key market trends, growth factors and opportunities
      • 7.2.5.2.2 Market size and forecast, by Formulation
      • 7.2.5.2.3 Market size and forecast, by Drug Type
      • 7.2.5.2.4 Market size and forecast, by Distribution Channel
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Key market trends, growth factors and opportunities
      • 7.2.5.3.2 Market size and forecast, by Formulation
      • 7.2.5.3.3 Market size and forecast, by Drug Type
      • 7.2.5.3.4 Market size and forecast, by Distribution Channel
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Formulation
    • 7.3.3 Europe Market size and forecast, by Drug Type
    • 7.3.4 Europe Market size and forecast, by Distribution Channel
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Key market trends, growth factors and opportunities
      • 7.3.5.1.2 Market size and forecast, by Formulation
      • 7.3.5.1.3 Market size and forecast, by Drug Type
      • 7.3.5.1.4 Market size and forecast, by Distribution Channel
      • 7.3.5.2 France
      • 7.3.5.2.1 Key market trends, growth factors and opportunities
      • 7.3.5.2.2 Market size and forecast, by Formulation
      • 7.3.5.2.3 Market size and forecast, by Drug Type
      • 7.3.5.2.4 Market size and forecast, by Distribution Channel
      • 7.3.5.3 UK
      • 7.3.5.3.1 Key market trends, growth factors and opportunities
      • 7.3.5.3.2 Market size and forecast, by Formulation
      • 7.3.5.3.3 Market size and forecast, by Drug Type
      • 7.3.5.3.4 Market size and forecast, by Distribution Channel
      • 7.3.5.4 Italy
      • 7.3.5.4.1 Key market trends, growth factors and opportunities
      • 7.3.5.4.2 Market size and forecast, by Formulation
      • 7.3.5.4.3 Market size and forecast, by Drug Type
      • 7.3.5.4.4 Market size and forecast, by Distribution Channel
      • 7.3.5.5 Spain
      • 7.3.5.5.1 Key market trends, growth factors and opportunities
      • 7.3.5.5.2 Market size and forecast, by Formulation
      • 7.3.5.5.3 Market size and forecast, by Drug Type
      • 7.3.5.5.4 Market size and forecast, by Distribution Channel
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Key market trends, growth factors and opportunities
      • 7.3.5.6.2 Market size and forecast, by Formulation
      • 7.3.5.6.3 Market size and forecast, by Drug Type
      • 7.3.5.6.4 Market size and forecast, by Distribution Channel
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Formulation
    • 7.4.3 Asia-Pacific Market size and forecast, by Drug Type
    • 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 China
      • 7.4.5.1.1 Key market trends, growth factors and opportunities
      • 7.4.5.1.2 Market size and forecast, by Formulation
      • 7.4.5.1.3 Market size and forecast, by Drug Type
      • 7.4.5.1.4 Market size and forecast, by Distribution Channel
      • 7.4.5.2 India
      • 7.4.5.2.1 Key market trends, growth factors and opportunities
      • 7.4.5.2.2 Market size and forecast, by Formulation
      • 7.4.5.2.3 Market size and forecast, by Drug Type
      • 7.4.5.2.4 Market size and forecast, by Distribution Channel
      • 7.4.5.3 Australia
      • 7.4.5.3.1 Key market trends, growth factors and opportunities
      • 7.4.5.3.2 Market size and forecast, by Formulation
      • 7.4.5.3.3 Market size and forecast, by Drug Type
      • 7.4.5.3.4 Market size and forecast, by Distribution Channel
      • 7.4.5.4 South Korea
      • 7.4.5.4.1 Key market trends, growth factors and opportunities
      • 7.4.5.4.2 Market size and forecast, by Formulation
      • 7.4.5.4.3 Market size and forecast, by Drug Type
      • 7.4.5.4.4 Market size and forecast, by Distribution Channel
      • 7.4.5.5 Rest of Asia-Pacific
      • 7.4.5.5.1 Key market trends, growth factors and opportunities
      • 7.4.5.5.2 Market size and forecast, by Formulation
      • 7.4.5.5.3 Market size and forecast, by Drug Type
      • 7.4.5.5.4 Market size and forecast, by Distribution Channel
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Formulation
    • 7.5.3 LAMEA Market size and forecast, by Drug Type
    • 7.5.4 LAMEA Market size and forecast, by Distribution Channel
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Key market trends, growth factors and opportunities
      • 7.5.5.1.2 Market size and forecast, by Formulation
      • 7.5.5.1.3 Market size and forecast, by Drug Type
      • 7.5.5.1.4 Market size and forecast, by Distribution Channel
      • 7.5.5.2 South Africa
      • 7.5.5.2.1 Key market trends, growth factors and opportunities
      • 7.5.5.2.2 Market size and forecast, by Formulation
      • 7.5.5.2.3 Market size and forecast, by Drug Type
      • 7.5.5.2.4 Market size and forecast, by Distribution Channel
      • 7.5.5.3 Saudi Arabia
      • 7.5.5.3.1 Key market trends, growth factors and opportunities
      • 7.5.5.3.2 Market size and forecast, by Formulation
      • 7.5.5.3.3 Market size and forecast, by Drug Type
      • 7.5.5.3.4 Market size and forecast, by Distribution Channel
      • 7.5.5.4 Rest of LAMEA
      • 7.5.5.4.1 Key market trends, growth factors and opportunities
      • 7.5.5.4.2 Market size and forecast, by Formulation
      • 7.5.5.4.3 Market size and forecast, by Drug Type
      • 7.5.5.4.4 Market size and forecast, by Distribution Channel

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 Pfizer Inc.
    • 9.1.1 Company overview
    • 9.1.2 Company snapshot
    • 9.1.3 Operating business segments
    • 9.1.4 Product portfolio
    • 9.1.5 Business performance
    • 9.1.6 Key strategic moves and developments
  • 9.2 Sanofi
    • 9.2.1 Company overview
    • 9.2.2 Company snapshot
    • 9.2.3 Operating business segments
    • 9.2.4 Product portfolio
    • 9.2.5 Business performance
    • 9.2.6 Key strategic moves and developments
  • 9.3 Merck and Company
    • 9.3.1 Company overview
    • 9.3.2 Company snapshot
    • 9.3.3 Operating business segments
    • 9.3.4 Product portfolio
    • 9.3.5 Business performance
    • 9.3.6 Key strategic moves and developments
  • 9.4 GSK
    • 9.4.1 Company overview
    • 9.4.2 Company snapshot
    • 9.4.3 Operating business segments
    • 9.4.4 Product portfolio
    • 9.4.5 Business performance
    • 9.4.6 Key strategic moves and developments
  • 9.5 johnson and johnson md&d
    • 9.5.1 Company overview
    • 9.5.2 Company snapshot
    • 9.5.3 Operating business segments
    • 9.5.4 Product portfolio
    • 9.5.5 Business performance
    • 9.5.6 Key strategic moves and developments
  • 9.6 Abbott Laboratories
    • 9.6.1 Company overview
    • 9.6.2 Company snapshot
    • 9.6.3 Operating business segments
    • 9.6.4 Product portfolio
    • 9.6.5 Business performance
    • 9.6.6 Key strategic moves and developments
  • 9.7 CELON LABORATORIES LIMITED
    • 9.7.1 Company overview
    • 9.7.2 Company snapshot
    • 9.7.3 Operating business segments
    • 9.7.4 Product portfolio
    • 9.7.5 Business performance
    • 9.7.6 Key strategic moves and developments
  • 9.8 Sun Pharmaceuticals Ltd
    • 9.8.1 Company overview
    • 9.8.2 Company snapshot
    • 9.8.3 Operating business segments
    • 9.8.4 Product portfolio
    • 9.8.5 Business performance
    • 9.8.6 Key strategic moves and developments
  • 9.9 Astellas Pharma Inc.
    • 9.9.1 Company overview
    • 9.9.2 Company snapshot
    • 9.9.3 Operating business segments
    • 9.9.4 Product portfolio
    • 9.9.5 Business performance
    • 9.9.6 Key strategic moves and developments
  • 9.10 Cipla Ltd
    • 9.10.1 Company overview
    • 9.10.2 Company snapshot
    • 9.10.3 Operating business segments
    • 9.10.4 Product portfolio
    • 9.10.5 Business performance
    • 9.10.6 Key strategic moves and developments
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제